Acute challenge with apomorphine in Huntington's disease: a double-blind study

Area of Science:

• Neurology
• Pharmacology

Background:

• Huntington's disease is a progressive neurodegenerative disorder characterized by motor, cognitive, and psychiatric dysfunction.
• Chorea, involuntary jerky movements, is a hallmark motor symptom of Huntington's disease.

Purpose of the Study:

• To evaluate the acute effects of apomorphine on chorea and other clinical features in patients with Huntington's disease.
• To assess the efficacy and time course of apomorphine's symptomatic treatment in Huntington's disease.

Main Methods:

• A double-blind, placebo-controlled study involving patients with Huntington's disease.
• Acute administration of apomorphine (1.5 mg or 3 mg) or placebo.
• Patients were assessed using a Huntington's disease rating scale at baseline and every 15 minutes for 2 hours post-administration.

Main Results:

• Apomorphine significantly improved the total score for Huntington's disease symptoms compared to placebo.
• Significant reductions in chorea intensity were observed, with an average improvement of 35.25% at 1.5 mg and 30.41% at 3 mg.
• Apomorphine also improved motor impersistence, associated movements, and vertical gaze, indicating broader symptomatic relief.

Conclusions:

• Apomorphine provides transient symptomatic improvement in chorea and associated clinical features of Huntington's disease.
• The antichoreic effects observed suggest a potential therapeutic role for apomorphine in managing motor symptoms.
• The time course of apomorphine's action warrants further investigation in relation to its known antiparkinsonian effects.